Shilanski & Associates, Inc. Argenx Se Transaction History

Shilanski & Associates, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$257.11 - $319.92 $395,949 - $492,676	-1,540 Closed	0 $0
Q1 2021 Apr 14, 2021	SELL	$268.3 - $380.31 $11,805 - $16,733	-44 Reduced 2.78%	1,540 $424,000
Q4 2020 Feb 03, 2021	SELL	$248.13 - $308.36 $11,413 - $14,184	-46 Reduced 2.82%	1,584 $466,000
Q3 2020 Nov 12, 2020	BUY	$215.51 - $272.51 $431 - $545	2 Added 0.12%	1,630 $428,000
Q2 2020 Jul 31, 2020	BUY	$127.44 - $232.72 $12,871 - $23,504	101 Added 6.61%	1,628 $367,000
Q1 2020 Apr 14, 2020	BUY	$108.83 - $165.23 $4,244 - $6,443	39 Added 2.62%	1,527 $201,000
Q4 2019 Jan 30, 2020	BUY	$106.59 - $164.21 $158,605 - $244,344	1,488 New	1,488 $239,000
Q3 2019 Oct 25, 2019	SELL	$113.31 - $150.51 $172,004 - $228,474	-1,518 Closed	0 $0
Q2 2019 Aug 05, 2019	BUY	$115.0 - $141.58 $174,570 - $214,918	1,518 New	1,518 $215,000

413

31M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $36.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Shilanski & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Shilanski & Associates, Inc. with notifications on news.